Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

This one is a hard pill to swallow. Eli Lilly and Co. (LLY)  and AstraZeneca PLC (AZN)  have discontinued late-stage trials of their experimental Alzheimer's disease drug lanabecestat, sending both companies' stock prices down Tuesday.

AstraZeneca's stock fell 22 cents to close at $36.16 a share, while Lilly dropped 35 cents to $85.49.

A committee from Internal Displacement Monitoring Centre, a third-party data-monitoring group, recommended to officials to halt the trials because it found that lanabecestat didn't work in two trials set up to help patients with early onset and mild dementia, according to the two companies.

"The complexity of Alzheimer's disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from the devastating disease," Dr. Daniel Skovronsky, president of Lilly Research Labs, said in the statement.

Despite the news, Morningstar analyst Damien Conover reiterated his "Hold" rating on AZN. (He doesn't cover LLY.)

Conover told TheStreet that "from our viewpoint, studies in Alzheimer's disease are highly risky, as the science is still developing in how to treat it. Our valuation of these companies developing Alzheimer's drugs is with a higher degree of uncertainty."

(This story has been updated to include closing stock prices.)

More from Stocks

Cramer: Amazon Will Be an 'Outsized Winner' When Consumer Trends Shift Online

Cramer: Amazon Will Be an 'Outsized Winner' When Consumer Trends Shift Online

It Is Better to Be Late Than Early When It Comes to Stock Market Turns

It Is Better to Be Late Than Early When It Comes to Stock Market Turns

Facebook, Fiat Chrysler, China Stocks and CBS - 5 Things You Must Know

Facebook, Fiat Chrysler, China Stocks and CBS - 5 Things You Must Know

How to Play Ford, Despite Its Lousy Chart: Market Recon

How to Play Ford, Despite Its Lousy Chart: Market Recon

Jim Cramer: Last Week's Breakdown Was Totally Dispiriting

Jim Cramer: Last Week's Breakdown Was Totally Dispiriting